People threatened by accidental exposure to foods they’re allergic to may have a new weapon of defense: On Friday, the U.S. Food and Drug Administration expanded the use of the asthma drug Xolair to help prevent anaphylactic reactions.
Xolair (omalizumab) is an injected drug and is not meant as a substitute for EpiPens or other anaphylaxis rescue remedies, the agency stressed.
Instead, “Xolair is intended for repeated use to reduce the risk of allergic reactions” if and when they occur, the FDA explained in a news release.
